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(13–31) and 6 (2–12). A human factors analysis of the
circumstances of each case attributed 79% to a combi-
nation of user error and device malfunction or ﬂawed
alarm design. None of the events were documented in the
medical record or in incident reports. CONCLUSIONS:
Rates of alarm related problems in two ICUs were much
higher than reported in a routine reporting system and
indicate an understudied important threat to patient
safety. An assessment of risk factors for these events is in
progress.
ARTHRITIS/OSTEOPOROSIS—Clinical
Outcomes/Healthcare Policy
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USE OF ALTERNATIVE THERAPY, QUALITY OF
LIFE,AND HEALTHCARE SPENDING IN
CHINESE PATIENTS WITH OSTEOARTHRITIS
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1The Chinese University of Hong Kong, Shatin, Hong Kong;
2The Chinese University of Hong Kong, Shatin, NT,
Hong Kong
OBJECTIVES: To describe the pattern of use of alterna-
tive therapy, healthcare spending, and health-related
quality of life in Chinese osteoarthritis (OA) patients in
Hong Kong. METHODS: We conducted a retrospective,
cross-sectional study of 547 adult Chinese patients in
Hong Kong who have been diagnosed as having OA. We
deﬁned the alternative therapy as 1 of the 11 therapies
outlined in international publications. OA patients who
used alternative therapies and those who did not were
compared for their socio-economic status, disease proﬁle,
personal healthcare spending, and quality of life. Quality
of life was measured using a Health Utility Index based
upon SF-36 health surveys. We further investigated the
association between the use of alternative therapies and
personal healthcare spending, and its association with the
Health Utility Index, in multivariate regressions control-
ling for socio-economic variables, years of OA, and the
severity of OA. RESULTS: Of the 547 OA patients, 219
(38.2%) had used 1 or more of the 11 alternative thera-
pies for OA. The most commonly used therapies, (and the
percentage of patients who used them), were acupuncture
(21.4%), exercise (12%), herbal remedy (5.9%), lifestyle
diets (5.8%), energy healing (4.4%), and chiropractic
manipulation (3.8%). On average, payment for alterna-
tive therapies constitutes 5% of the overall personal
healthcare spending, and 29% of the out-of-pocket pay-
ments. CONCLUSION: The use of alternative therapies
was statistically signiﬁcantly associated with higher per-
sonal healthcare spending, after adjusting for socioeco-
nomic variables, years of OA and severity of OA. The use
of alternative therapies was not signiﬁcantly associated
with an improvement in quality of life in the regression
analysis.
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HEALTH-RELATED OUTCOMES IN A MANAGED
CARE MEDICAID POPULATION
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OBJECTIVES: Prior authorization (PA) is a poorly
studied, but commonly employed policy used by health
care payers to manage the rising costs of pharmacy 
beneﬁts. Our objective was to evaluate the impact of PA
policies for cyclooxygenase-2 (COX-2) inhibitors on 
prescription drug and medical service utilization in a
managed care Medicaid population. METHODS: The
analysis was conducted from January 1, 1999 to October
31, 2001 when PA policies were enacted for celecoxib and
rofecoxib. Monthly annualized rates of utilization were
estimated using medical and prescription drug billing
records. An autocorrelation-corrected segmented linear
regression model was developed to evaluate trends in 
utilization temporally associated with PA initiation. 
The primary analysis evaluated utilization of related 
drug classes (e.g. conventional NSAIDs, PPIs), and ofﬁce,
emergency, and hospital encounters in all enrolled
members. A secondary analysis was performed in a
cohort of prior NSAID (conventional and COX-2) users.
RESULTS: After each PA was activated, utilization 
of celecoxib and rofecoxib were immediately reduced
from 1.07 to 0.53 days supply/person-year (58.9% re-
duction; 95% CI: 50.0%–67.9%) and 0.96 to 0.52 
days supply/person-year (49.8% reduction; 95% CI:
40.5%–59.1%), respectively. Growth in utilization was
slowed for both agents (p < 0.0001). Utilization changes
were not observed in other drug classes. Similar trends
were observed in the secondary analysis. No changes 
in medical service use were noted with the exception of
emergency room visits, which increased by 18.0% (95%
CI: 2.2%–33.9%) and exhibited a higher growth rate
after the PA for celecoxib was enacted. A similar, non-
signiﬁcant trend was observed in the secondary analysis.
CONCLUSIONS: Utilization of rofecoxib and celecoxib
was reduced substantially following the implementation
of a PA policy. No important concomitant changes in the
use of other drug classes were detected. The small increase
in ER visits observed after the celecoxib PA was activated
is a concerning ﬁnding that warrants further study.
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OBJECTIVES: To analyze the market impact of the in-
troduction of the COX-2 inhibitors, Celebrex and Vioxx,
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within the NSAID class and other therapeutic classes that
constitute the analgesic market. METHODS: The study
design was a retrospective study of paid pharmacy claims
for analgesic medications for a continuously insured pop-
ulation of 62,614 members from July 1996 to June 2001.
Claims were divided into seven therapeutic categories:
hydrocodone, narcotics, non-narcotics, newer NSAIDs
(Relafen, Daypro, Arthrotec), older NSAIDs, oxycodone,
and COX-2 inhibitors. Data of paid analgesic pharmacy
claims were analyzed by overall analgesic market pre-
scription claims, day supply, pain management therapies,
per diem cost (ingredient cost per day supply) and market
share per therapeutic category. RESULTS: Over the 5-
year period, claims increased 29.1% while day supply per
claim increased 17.7% for a total growth in day supply
of almost 52%. The proportion of the population who
used an analgesic also increased from 33.4% in the ﬁrst
year to 37.9% in the ﬁfth year. There was a 15% increase
in people receiving at least one analgesic prescription in
a year over the 5-year period. Per diem costs for the
market increased from $1.74 in the ﬁrst year to $2.20 
in the ﬁfth year. Per member per month costs increased
69.3% from $12.36 in the ﬁrst year to $20.93 in the ﬁfth
year. COX-2 inhibitors market share by day supply
increased from zero to 39.6%. The market share of the
newer NSAIDs decreased from 20.5% in the year prior
to the introduction of the COX-2 inhibitors (year 2) 
to 5.5% in the ﬁfth year. CONCLUSIONS: Based on 
day supply, the analgesic market grew almost 52% with
COX-2 inhibitors garnering 39.6% within 3 years of
market introduction. The COX-2’s beneﬁted from both
the growth in the market and reduction in market share
of the newer NSAIDs.
PAR4
ECONOMIC IMPLICATIONS OF NON-
COMPLIANCE WITH OSTEOPOROSIS
TREATMENT IN ACTUAL PRACTICE
Huybrechts K1, Caro J1, Ishak K2, Naujoks C3
1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Dorval, QC, Canada; 3Novartis Pharma AG, Basel,
Switzerland
OBJECTIVES: Although it is well recognized, in both
clinical research and actual practice, that non-compliance
with osteoporosis treatment is a problem, its economic
implications have not been well documented. The objec-
tive of this study was to quantify the implications of non-
compliance in terms of all-cause hospitalizations and total
costs. METHODS: Demographic, prescription drug use,
physician services and hospitalization information for
women with osteoporosis who were dispensed an osteo-
porosis medication between 1996 and 2001 was obtained
from the Saskatchewan Health data ﬁles. Subjects were
considered to be compliant over a given period of time if
they had medication available during 80% or more of
that time interval. Hospitalization rates and total costs in
various patient groups were compared using descriptive
analyses. The impact of compliance was assessed further
using regression analysis on the logarithmically trans-
formed total cost, controlling for prior history of hospi-
talizations (which was considered a proxy for morbidity).
RESULTS: A total of 11,249 women suffering from
osteoporosis were identiﬁed with an average follow-up of
2.3 years. More than half (50.6%) did not have medica-
tion available to cover at least 80% of the time they 
were followed and were thus considered non-compliant.
Overall, 48.5% of patients were hospitalized an average
of 2.7 times during follow-up. Non-compliant patients
were signiﬁcantly more likely to be hospitalized (54.3%)
than compliant patients (42.6%) (P < 0.0001). The total
monthly cost—including both hospitalization and physi-
cian service costs—was signiﬁcantly higher for non-
compliant ($245 CAD) than for compliant ($214 CAD)
patients (P < 0.05). The same trend was observed for both
cost components individually. The effect of compliance
on total cost was maintained after controlling for hospi-
talization history. CONCLUSION: The desired goal of
keeping patients with osteoporosis on chronic treatment
is not achieved adequately in actual practice and the cost
implications of this behavior are substantial.
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